| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06871e32ce0f0c3149618b8dc77181de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2db313c6837b9b66aaf8747c2c8423d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_57a2ea361ab8eaf230d4aacc29a463e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4cec10204b2bc78246ec0e76707b32ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1889c86c84d0f7089ceb763606c0c4db |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5146 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate |
2011-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_275c255f7552aa69132e96cd225ac9fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b9987626d4f6c33a284159a35619ce1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b2e318b14ed9bb705028b2c1b7870e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e77cdca62e351c8025ae124e76b31c9 |
| publicationDate |
2013-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013202706-A1 |
| titleOfInvention |
Nanostructured atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
| abstract |
The present invention is directed to nanostructured Atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Atorvastain, its pharmaceutically acceptable salts and compositions of them according to the invention have an average particle size of less than about 600 nm. The stable amorphous nanostructured particles of the present invention are characterized by increased solubility and bioequivalent biological performance compared to the marketed crystalline drug. Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9504652-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012244220-A1 |
| priorityDate |
2010-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |